Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

Author(s):

Benjamin Levy, MD, leads discussion on the promising potential of antibody-drug conjugates (ADCs) in treating non-small cell lung cancer (NSCLC) with non-actionable mutations, while Helena A. Yu, MD, presents an overview of the EVOKE-02 study, emphasizing key efficacy and safety data that could significantly impact the current treatment landscape.

EP: 1.Treatment Strategies for NSCLC with Non-Actionable Mutations

Now Viewing

EP: 2.Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

EP: 3.Exploring the TROPION-Lung04 Study

EP: 4.Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC

EP: 5.Navigating Between ADCs in NSCLC

EP: 6.Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

EP: 7.Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

EP: 8.MARIPOSA Study Insights

EP: 9.Optimizing Therapy Selection in EGFR Mutant NSCLC

EP: 10.ASCO 2024 Updates: Novel Approaches in NSCLC Therapy

EP: 11.Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC

EP: 12.Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape

EP: 13.Targeting of HER3: Insights from HERTHENA-Lung01

EP: 14.Challenges and Learnings from EVOKE-01

EP: 15.Key ADC Studies at ASCO 2024

EP: 16.Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

EP: 17.Patient Selection and Sequencing of NSCLC ADCs

Briefly discuss the potential role of ADCs in NSCLC with non-actionable mutations.
1. What is the rationale for use of ADCs in this treatment space?
2. What characteristics may allow ADCs to be more advantageous in this treatment space over other traditional chemotherapy and targeted agents?
3. Which ADCs are most likely to have potential benefit here and why?
Please review the rationale and study design for EVOKE-02 and discuss key efficacy and safety data and the implications these findings may have on the treatment landscape. (Garon, et al. J Clin Oncol, 2022; Cho, et al. WCLC 2023; Cappuzzo et al. WLC 2024. Efficacy results by histology from the EVOKE-2 study; ASCO 2024 Patel et al. SG + Pembro in 1L mNSCLC with PD-L1 ≥50%: Cohort A of EVOKE-02)
1. What do data demonstrateregarding the efficacy of SG + pembro in patients with NSCLC and how does response differ by PD-L1 expression?
2. Other key takeaways? What implications could these findings have on clinical practice?
3. Which patients stand to benefit the greatest from this treatment approach?